ArticleDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2019
A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.
Article in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- The Aberrant Expression of Biomarkers and Risk Prediction for Neoplastic Changes in Barrett's Esophagus-Dysplasia.Cancers · 2024Article
- Esophageal Mucosal Resistance in Reflux Esophagitis: What We Have Learned So Far and What Remains to Be Learned.Diagnostics (Basel, Switzerland) · 2023Review
- Prognostic, Diagnostic and Predictive Biomarkers in the Barrett's Oesophagus-Adenocarcinoma Disease Sequence.Cancers · 2022Review
- Prediction of neoplastic progression in Barrett's esophagus using nanoscale nuclear architecture mapping: a pilot study.Gastrointestinal endoscopy · 2022Article
- Agrin Loss in Barrett's Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Management of nondysplastic Barrett's esophagus: When to survey? When to ablate?Therapeutic advances in chronic disease · 2022Review
- Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.Cancer medicine · 2022Review
- The Top-Cited Articles With a Focus on Barrett's Esophagus: A Bibliometric Analysis.Frontiers in surgery · 2022Article
- Esophageal cancer: Epidemiology, risk factors and screening.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021Article
- Alteration of protein expression and spliceosome pathway activity during Barrett's carcinogenesis.Journal of gastroenterology · 2021Article
- The SpaTemp cohort: 168 nondysplastic Barrett's esophagus surveillance patients with and without progression to early neoplasia to evaluate the distribution of biomarkers over space and time.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2021Article
- Is Malignant Potential of Barrett's Esophagus Predictable by Endoscopy Findings?Life (Basel, Switzerland) · 2020Review
- A narrative review of Barrett's esophagus in 2020, molecular and clinical update.Annals of translational medicine · 2020Review
- Endoscopic eradication therapy for Barrett's oesophagus: state of the art.Current opinion in gastroenterology · 2020Review
- Article
- Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus.The American journal of gastroenterology · 2020Article
- Radiofrequency Ablation of Barrett's Esophagus: Have We Gone Too Far, or Not Far Enough?Current gastroenterology reports · 2020Review
- Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.Clinical and translational gastroenterology · 2020Article
- Risk of Cancer in Patients With Barrett Esophagus.Gastroenterology & hepatology · 2019Article
- Evolving screening and surveillance techniques for Barrett's esophagus.World journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 3 countries.
Funding
Abstract
Progression from Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) is uncommon but the consequences are serious. Predictors of progression are essential to optimize resource utilization. This study assessed the utility of a promising panel of biomarkers applicable to routine paraffin embedded biopsies (FFPE) to predict progression of BE to EAC in a large population-based, nested case-control study.We utilized the Amsterdam-based ReBus nested case-control cohort. BE patients who progressed to high-grade dysplasia (HGD)/EAC (n = 130) and BE patients who never progressed (n = 130) were matched on age, sex, length of the BE segment, and duration of endoscopic surveillance. All progressors had minimum 2 years of endoscopic surveillance without HGD/EAC to exclude prevalent neoplasia. We assessed abnormal DNA content, p53, Cyclin A, and Aspergillus oryzae lectin (AOL) in FFPE sections. We performed conditional logistic regression analysis to estimate odds ratio (OR) of progression based on biomarker status.Expert LGD (OR, 8.3; 95% CI, 1.7-41.0), AOL (3 vs. 0 epithelial compartments abnormal; OR, 3.6; 95% CI, 1.2-10.6) and p53 (OR, 2.3; 95% CI, 1.2-4.6) were independently associated with neoplastic progression. Cyclin A did not predict progression and DNA ploidy analysis by image cytometry was unsuccessful in the majority of cases, both were excluded from the multivariate analysis. The multivariable biomarker model had an area under the receiver operating characteristic curve of 0.73.Expert LGD, AOL, and p53 independently predict neoplastic progression in BE patients and are applicable to routine practice. These biomarkers can aid in selecting patients for endoscopic ablation or more intensive surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.